Fullife Healthcare Reports Revenue Growth and Profitability Enhancements
Fullife Healthcare, the parent entity of sports nutrition brands Fast&Up and Chicnutrix, showcased a 10% year-on-year revenue increase for the fiscal year concluding in March 2024. The company’s primary objective seemed to be on enhancing profitability, evidenced by a substantial 38.8% reduction in losses during the same timeframe.
Financial Overview for Fullife Healthcare
According to the consolidated annual results obtained from the Registrar of Companies (RoC), Fullife’s operational revenue surged to Rs 188 crore in the last fiscal year, a rise from Rs 171 crore recorded in FY23.
Brand Performance
Fast&Up provides active nutrition products such as protein supplements, workout aids, and immunity boosters. Another brand under Fullife, Chicnutrix, launched in 2019, emphasises women’s wellness, offering items for skincare, haircare, PCOS support, UTI care, and additional health needs. Revenue generated from these products constituted the firm’s only income source for the preceding fiscal year.
In addition, the company gained Rs 3.8 crore from non-operational channels, culminating in a total revenue of Rs 191 crore for FY24.
Cost Management Strategies
For the sports nutrition brand, procurement costs represented 39% of overall expenditures, rising by 3.6% to Rs 87 crore in FY24. Fullife successfully trimmed its advertising expenses by 22% down to Rs 46 crore.
Employee and Operational Costs
Employee expenses saw a rise of 15.6% reaching Rs 37 crore in FY24. Other costs including freight, online sales, legal matters, and miscellaneous overheads increased the overall expenditure to Rs 222 crore for FY24. Various sources provide a detailed breakdown of these expenses.
Loss Reduction and Financial Metrics
Despite modest growth figures, effective cost-management practices allowed Fullife to cut its losses by 38.8%, bringing it down to Rs 30 crore in FY24, in comparison to Rs 49 crore in FY23. On a unit basis, the firm spent Rs 1.18 to generate a rupee of revenue during the last fiscal year. By the closure of FY24, Fullife’s Return on Capital Employed (ROCE) and EBITDA margin improved to -30.7% and -13.09%, respectively. The Mumbai-based enterprise reported total current assets amounting to Rs 111 crore.
Investment Insights
To date, Fullife Healthcare has secured over $40 million in funding, including a notable $22 million received from Morgan Stanley in 2021. Reports from various sources indicate that Morgan Stanley holds the largest share at 27.35%, followed by Rakesh Jhunjhunwala, a prominent investor who passed away in August 2022.
Challenges in the Nutrition Sector
The surge in companies and brands within the nutrition industry has led to the challenging reality that, despite the expanding market size and segments, achieving profitability is significantly tougher than anticipated during initial ventures. Enhanced distribution channels, particularly through e-commerce, have disrupted traditional business barriers, causing many companies to grapple with finding a balance between growth and profitability. The market segment valued between Rs 150-200 crore is particularly notable, where many firms recognize their potential market validation but find achieving profitable operations amidst fierce competition to be profoundly challenging.
With minimal interest in a Direct-to-Consumer model that consolidates various brands, it is likely that more businesses will pivot towards becoming robust and profitable regional entities rather than maintaining large-scale, loss-incurring operations.
